Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Amusategui
I
I
Facultad de Veterinaria, Universidad Complutense de Madrid, Spain.
Sainz
A
A
Tesouro
M A
MA
D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000965:Antimony / Q000008:administration & dosage / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D007273:Injections, Intramuscular; D007896:Leishmaniasis / Q000188:drug therapy / Q000662:veterinary*; D008536:Meglumine / Q000008:administration & dosage / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D012044:Regression Analysis; D013997:Time Factors
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D000493:Allopurinol; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony